drugset / Trial / NCT00289796

Assess Feasibility of an Acellular Pertussis Vaccine (Pa) Given Soon After Birth, Followed by 3-dose Primary Vaccination With the DTPa-HBV-IPV/Hib Vaccine

NCT00289796 ↗

Phase 2 Completed 121 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindPrevention

Summary

This study will assess immunogenicity, safety and reactogenicity of primary and booster vaccination.

Timeline

Start
2004-07
Primary completion
2006-04
Completion
2006-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator DTPa-HBV-IPV/Hib Vaccine — Intramuscular